Skip to main content

$0.155 0.005 (3.33%)

High

$0.16

Low

$0.15

Trades

7

Turnover

$4,468

Volume

29,243
30 June 2023 at 3:01pm
Register to track FRE and receive email alerts.

Nasodine in vitro and pilot human COVID-19 studies published

StockBot

416,823 posts

FRE released this announcement to the ASX on 10 February 2022, 9:30. The announcement is not marked as price sensitive, and is 2 page(s) in length and 150.05kb in size.

You can view all announcements from FRE and see how they appear on a price chart on the announcements page.

At the date of this announcement, FRE was 0.006% short sold according to ASIC data. It was ranked the 577th most shorted stock on the ASX. It remains ranked 620th as of the latest reported data (14 July 2025).

Other Recent Announcements from FRE
Firebrick Update on AAT Schedule 29 June 2023, 16:23
Cleansing Notice 21 June 2023, 14:38
Change of Director's Interest Notice - Stephen Goodall 21 June 2023, 14:36
Nasodine in vitro and pilot human COVID-19 studies published 10 February 2022, 9:30
Nasodine COVID-19 trial receives SAHPRA approval 1 February 2022, 9:50
Becoming a substantial holder - Stephen Goodall 25 January 2022, 13:20
Becoming a substantial holder - Peter Molloy 25 January 2022, 13:19
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track FRE and receive email alerts.